Pseudoprogression during Tirabrutinib treatment

4 evidence topics · 1 source

Objective

Location and study date

No evidence found.

Study design

Eligibility criteria

Not applicable.

Treatment

Continued treatment

“TIR monotherapy” (opens the source at this quote in a new tab)

Study outcomes

Rationale for using radiological response as an observed outcome

Not applicable.

Statistical analysis description

Number of participants (Planned and analyzed)

Description of analysis sets

Not applicable.

Results

Participant disposition

No evidence found.

Baseline characteristics

Age and disease distribution

“A 79-year-old woman had relapsed PCNSL with multiple tumor lesions in the lateral ventricles.” (opens the source at this quote in a new tab)

Efficacy results

Clinical course despite radiological enlargement

“Despite the enlarged tumors, the patient remained asymptomatic, and re-remission was achieved by continuation of TIR monotherapy.” (opens the source at this quote in a new tab)

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations

Summary

This single case describes radiological enlargement followed by re-remission during continued tirabrutinib monotherapy. It does not establish the frequency of pseudoprogression or justify assuming that enlargement during treatment is benign in other participants.